Mainz Biomed Collaborates with Liquid Biosciences to Develop AI Enables Screening Tests for Colorectal Cancer
Shots:
- Under the terms of the extended agreement, Mainz Biomed will utilize Liquid Biosciences’ EMERGE platform to include the analysis of Mainz’s eAArly DETECT & ReconAAsense studies. Both companies expect to develop self-administrable cancer detection products
- The eAArly DETECT study evaluates 265 individuals with colorectal cancer across 22 sites (results expected by Q4’23) whereas the ReconAAsense study is an upcoming US pivotal FDA PMA trial. Earlier, Liquid Biosciences’ EMERGE platform was used by Mainz to analyze its ColoFuture study
- The completion of the studies will lead to a single fixed ML/AI-based algorithm (developed using the EMERGE platform) incorporated into the test report
Ref: Globenewswire | Image: Mainz Biomed
Related News:- The US FDA Approved Recor Medical and Otsuka Medical Devices’ Paradise Ultrasound Renal Denervation System for Hypertension
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
